AU2003291337B2 - Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same - Google Patents

Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same Download PDF

Info

Publication number
AU2003291337B2
AU2003291337B2 AU2003291337A AU2003291337A AU2003291337B2 AU 2003291337 B2 AU2003291337 B2 AU 2003291337B2 AU 2003291337 A AU2003291337 A AU 2003291337A AU 2003291337 A AU2003291337 A AU 2003291337A AU 2003291337 B2 AU2003291337 B2 AU 2003291337B2
Authority
AU
Australia
Prior art keywords
compound
dehydroepothilone
epothilone
oxo
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003291337A
Other languages
English (en)
Other versions
AU2003291337A1 (en
Inventor
Yong Li
David Myles
Kurt Sundermann
Li Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of AU2003291337A1 publication Critical patent/AU2003291337A1/en
Application granted granted Critical
Publication of AU2003291337B2 publication Critical patent/AU2003291337B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2003291337A 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same Ceased AU2003291337B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42535202P 2002-11-07 2002-11-07
US60/425,352 2002-11-07
US47374303P 2003-05-27 2003-05-27
US60/473,743 2003-05-27
PCT/US2003/035411 WO2004043954A2 (en) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same

Publications (2)

Publication Number Publication Date
AU2003291337A1 AU2003291337A1 (en) 2004-06-03
AU2003291337B2 true AU2003291337B2 (en) 2010-09-09

Family

ID=32314587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291337A Ceased AU2003291337B2 (en) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same

Country Status (14)

Country Link
US (2) US20040152708A1 (US20040106767A1-20040603-C00005.png)
EP (3) EP1562941B1 (US20040106767A1-20040603-C00005.png)
JP (3) JP4641941B2 (US20040106767A1-20040603-C00005.png)
KR (2) KR100966667B1 (US20040106767A1-20040603-C00005.png)
AT (1) ATE452888T1 (US20040106767A1-20040603-C00005.png)
AU (1) AU2003291337B2 (US20040106767A1-20040603-C00005.png)
CA (1) CA2505368C (US20040106767A1-20040603-C00005.png)
CY (1) CY1110295T1 (US20040106767A1-20040603-C00005.png)
DE (1) DE60330703D1 (US20040106767A1-20040603-C00005.png)
DK (1) DK1562941T3 (US20040106767A1-20040603-C00005.png)
ES (2) ES2336911T3 (US20040106767A1-20040603-C00005.png)
PT (1) PT1562941E (US20040106767A1-20040603-C00005.png)
SI (1) SI1562941T1 (US20040106767A1-20040603-C00005.png)
WO (1) WO2004043954A2 (US20040106767A1-20040603-C00005.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2336911T3 (es) * 2002-11-07 2010-04-19 Kosan Biosciences, Inc. Trans-9,10-dehidroepotilonas c y d, sus analogos y procedimientos de preparacion.
CN101088998A (zh) * 2002-11-07 2007-12-19 科桑生物科学公司 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
US20050002983A1 (en) * 2003-03-28 2005-01-06 Johnson Robert G. Devices, methods, and compositions to prevent restenosis
CA2539801A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
JP5656407B2 (ja) * 2006-12-14 2015-01-21 エイルロン セラピューティクス，インコーポレイテッド ビス−スルフヒドリル大環状化系
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2564862B1 (en) 2007-02-23 2017-08-02 Aileron Therapeutics, Inc. Substituted amino acids for preparing triazole linked macrocyclic peptides
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907480A1 (de) * 1999-02-11 2000-08-17 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU2003260002A1 (en) * 2002-08-23 2004-03-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0706373T3 (da) 1992-03-23 2000-09-18 Univ Georgetown Liposomindkapslet taxol og en fremgangsmåde til anvendelse heraf
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
SI0932399T1 (sl) 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BR9907647B1 (pt) 1998-02-05 2014-04-01 Novartis Ag Novartis S A Novartis Inc Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19954229A1 (de) * 1999-11-04 2001-05-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
KR20070058028A (ko) 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
KR20070092334A (ko) 2000-04-28 2007-09-12 코산 바이오사이언시즈, 인코포레이티드 폴리케타이드의 제조방법
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030176368A1 (en) * 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2336911T3 (es) * 2002-11-07 2010-04-19 Kosan Biosciences, Inc. Trans-9,10-dehidroepotilonas c y d, sus analogos y procedimientos de preparacion.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907480A1 (de) * 1999-02-11 2000-08-17 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU2003260002A1 (en) * 2002-08-23 2004-03-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Also Published As

Publication number Publication date
JP5679757B2 (ja) 2015-03-04
US20090186927A1 (en) 2009-07-23
KR100996996B1 (ko) 2010-11-25
EP1562941A2 (en) 2005-08-17
KR20050084959A (ko) 2005-08-29
DE60330703D1 (de) 2010-02-04
JP2011006480A (ja) 2011-01-13
PT1562941E (pt) 2010-01-25
JP2013213054A (ja) 2013-10-17
KR20100018075A (ko) 2010-02-16
DK1562941T3 (da) 2010-04-19
EP2135867B1 (en) 2013-09-25
SI1562941T1 (sl) 2010-05-31
JP2006510743A (ja) 2006-03-30
ES2436296T3 (es) 2013-12-30
ES2336911T3 (es) 2010-04-19
CA2505368C (en) 2011-09-20
EP1562941B1 (en) 2009-12-23
WO2004043954A3 (en) 2004-11-18
KR100966667B1 (ko) 2010-06-29
AU2003291337A1 (en) 2004-06-03
CA2505368A1 (en) 2004-05-27
CY1110295T1 (el) 2015-01-14
EP2135867A1 (en) 2009-12-23
EP2135868A1 (en) 2009-12-23
JP4641941B2 (ja) 2011-03-02
ATE452888T1 (de) 2010-01-15
WO2004043954A2 (en) 2004-05-27
US20040152708A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
AU2003291337B2 (en) Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same
JP2006510743A5 (US20040106767A1-20040603-C00005.png)
US20020045609A1 (en) Epothilone derivatives and methods for making and using the same
US6489314B1 (en) Epothilone derivatives and methods for making and using the same
US6893859B2 (en) Epothilone derivatives and methods for making and using the same
US6589968B2 (en) Epothilone compounds and methods for making and using the same
WO2002080846A2 (en) Epothilone derivatives and methods for making and using the same
US20020058286A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
US20030023082A1 (en) Epothilone derivatives and methods for making and using the same
CA2401800A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
US20020058817A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
CN101519404A (zh) 15环噻酮衍生物及其制备方法与应用
US20030134883A1 (en) 14-Methyl-epothilones
US7070964B2 (en) Epothilone compounds and methods for making the same
US20080280973A1 (en) Laulimalide Analogues as Therapeutic Agents
CN1330648C (zh) 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
WO2009052507A1 (en) Bryostatin analogues, synthetic methods and uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired